Actively Recruiting
Neural and Psychiatric Consequences of Cannabis Use in Adolescents
Led by University of Miami · Updated on 2026-04-22
280
Participants Needed
2
Research Sites
221 weeks
Total Duration
On this page
Sponsors
U
University of Miami
Lead Sponsor
N
Nathan Kline Institute for Psychiatric Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to investigate the effects of cannabis on brain function among adolescents with depression.
CONDITIONS
Official Title
Neural and Psychiatric Consequences of Cannabis Use in Adolescents
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cannabis users with significant use defined as self-reported use on 10 or more of the prior 30 days and positive THC urine test
- Adolescents aged 14 to 20 years
- Participants with depressive symptoms including subthreshold depression (CDRS-R score >=30 for ages 14-17, MADRS score >=12 for ages 18-20) or major depressive disorder by MINI diagnosis
- At least 50% of depressed participants to have CDRS-R score >=40 or MADRS score >=20
- Psychotropic medication free for more than one month (or three months for long half-life medications) prior to enrollment
- Participants able to undergo MRI without contraindications
- Oral contraceptive use allowed and controlled for
- Healthy controls with no lifetime major psychiatric diagnosis and no THC use
You will not qualify if you...
- Use of psychotropic medications within one month (or three months for long half-life drugs) prior to enrollment
- MRI contraindications such as claustrophobia, metallic ink tattoos, orthodontic braces, or pacemakers
- Positive pregnancy test
- Neurological illnesses or medical conditions like multiple sclerosis or rheumatoid arthritis
- Estimated IQ of 80 or lower
- Current substance use disorders other than cannabis or nicotine
- Hazardous alcohol use or DSM-5 alcohol use disorder (AUDIT-C >5)
- Medical cannabis certification or intention to become certified
- Current stimulant use (methamphetamine or cocaine) by self-report or urine test
- DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and non-cannabis substance-related disorders in depressed THC non-users
- Imminent suicide risk or active suicidal ideation requiring emergency intervention in depressed participants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
University of Miami Clinical Research Building
Miami, Florida, United States, 33136
Actively Recruiting
2
Nathan Kline Institute
Orangeburg, New York, United States, 10962
Not Yet Recruiting
Research Team
V
Vilma Gabbay, MD, JD, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here